Primary cardiac tumors, which originate from the heart, are uncommon and can be classified as benign or malignant, with the majority being benign. Malignant primary cardiac tumors have a poor prognosis. Benign ones may also cause severe hemodynamic and electrophysiological consequences, but the prognosis is generally good if they are detected early and treated properly. In recent years, researches on the genetic and molecular causes of primary cardiac tumors have yielded some promising breakthroughs, with some of them already being translated into clinical practice. This article reviews research progress and its use in precise diagnosis and targeted therapy from the perspective of DNA, RNA, and protein changes, as well as prospects the promising research directions in the future.
ObjectiveTo investigate a more convenient and safe sampling method for viral nucleic acid detection of coronavirus disease 2019.MethodsAn oropharyngeal swab and nasopharyngeal swab were simultaneously taken from 100 patients with coronavirus disease 2019 in a hospital in Wuhan. Then the efficacies of two sampling methods were compared on the positive rates of viral nucleic acid detection.ResultsThe positive rate for SARS-CoV-2 was 54% in oropharyngeal swabs, while 89% positive in nasopharyngeal swabs. There was a significant difference in the detection rate between oropharyngeal swab and nasopharyngeal swab (χ2=3.850 4, P=0.049 7).ConclusionsThe positive rate for nucleic acid testing from nasopharyngeal swabs are significantly better than that from oropharyngeal swabs. Therefore, sampling by nasopharyngeal swabs, rather than oropharyngeal swabs, should be chosen as the preferred virological screening method for patients with coronavirus disease 2019.
